This requires too many leaps of faith to state a claim either way (with respect to muscle anabolism).
What I can say is that I can make a case for Primo but not EQ use on the basis of anything tangible. Of course, this doesn't mean that if you like EQ, don't use it; and I do not address EQ's use for women, for whom it is particularly outstanding (perhaps indicating some intangible qualities that it possesses). So feel free to handwave, "meh, maybe on paper" away; but I will just defend this post by pointing out that it's not only typed out ("on paper") but also reasoned out.
Removing any influence of relative parent hormone content between the undecylenate & enanthate esters (where enanthate > undecylenate, i.e., Primo > EQ), we can say that boldenone is a surprisingly weak anabolic agent, with a low potency to activate the AR (10.72% relative potency vs. DHT). Metenolone is considerably more potent as an AR ligand (28.75% relative potency vs. DHT).
However, metenolone is principally metabolized by 3α-HSD (like DHT), ubiquitious in human skeletal muscle, meaning that it is basically broken down rapidly in muscle (in humans) before it is able to exert substantial muscle anabolism.
I can make a much stronger case for rational metenolone use vs. boldenone, as metenolone does pose somewhat reduced cardiac harm risks and is a commercially available (i.e., pharmaceutical) parenteral (i.m.) 5α-reduced AAS.
Boldenone basically does what nandrolone and testosterone do (augments IGF-I, increasing total-body size), but with risks attendant to veterinary & black market drug supplies, without offering any unique benefit. Unique benefits of testosterone include its 5α-reduction & supporting sexual function, and of nandrolone include its increasing matrix type I collagen deposition & fluid retention in synovial joints, benefiting joints acutely (but also posing unique cardiac harms).